Danish Beverage Stock News

Novo Nordisk announced a major expansion of its oral GLP-1 manufacturing facility in Ireland, aimed at increasing capacity for obesity and diabetes treatments. The company also entered a new $2.1b partnership with Vivtex to co-develop next generation oral biologic therapies. Both moves focus on oral delivery of GLP-1 and other biologics at a time of strong global demand for obesity and diabetes drugs. For investors watching CPSE:NOVO B, these moves come after a challenging share price...

CEO transition puts leadership in focus for Bavarian Nordic (CPSE:BAVA) Bavarian Nordic (CPSE:BAVA) has moved into the spotlight after announcing that long-serving CEO Paul Chaplin will step down for personal reasons. The board is now beginning the search for his successor. See our latest analysis for Bavarian Nordic. Beyond the CEO news, Bavarian Nordic’s shares have been relatively steady, with a 1-year total shareholder return of 18.16% and more muted recent share price returns around the...

Scandinavian Tobacco Group (CPSE:STG) is back in focus after its UK arm revealed a full rebrand of the XQS nicotine pouch range, featuring new packaging, a new logo and detailed flavour profile indicators. See our latest analysis for Scandinavian Tobacco Group. The rebrand lands at a time when momentum in the shares has been relatively positive, with a 30 day share price return of 6.91% and a 90 day share price return of 12.85%. This supports a 5 year total shareholder return of 28.64% at a...

Société Générale has cut its shareholding in ISS A/S (CPSE:ISS) to below 5%, triggering a regulatory disclosure of a change in major shareholder status. The move marks a shift in ISS’s ownership structure that investors may watch for potential implications for governance and market sentiment. ISS, listed as CPSE:ISS, is a global facility services provider. Changes in its major shareholders tend to catch the eye of investors who follow long contract cycles and customer retention trends. The...

ALK-Abelló A/S recently reported full-year 2025 results showing sales of DKK 6,312 million and net income of DKK 1,197 million, confirmed an 11–15% local-currency revenue growth outlook for 2026, announced an annual dividend of DKK 1.60 per share, and disclosed that EVP of R&D Henriette Mersebach will step down in February 2026 while supporting the transition. The combination of stronger earnings, growth guidance under the Allergy+ strategy, and a planned change in R&D leadership highlights...

NKT (CPSE:NKT) is in focus after its 2025 annual results, where the company reported record-high revenue, strong operational EBITDA, and a sizeable high voltage order backlog, alongside its new Charging Forward plan and 2026 outlook. See our latest analysis for NKT. The latest results and 2026 outlook have arrived after a strong run for investors, with the 1 year total shareholder return at 67.24% and the 5 year total shareholder return at 295.98%. Recent share price momentum around DKK819.5...

Why Gubra’s latest earnings are drawing fresh attention Gubra (CPSE:GUBRA) has jumped onto investors’ radars after its 2025 earnings call, where the company reported record revenue and operating profit, alongside a sizeable upfront payment from outlicensing its EM compound. See our latest analysis for Gubra. The earnings news arrives after a sharp 18.48% 1 day share price return. However, the stock still shows a 26.78% year to date share price decline and a 21.55% 1 year total shareholder...

On 20 February 2026, RWE announced a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Vanguard West offshore wind project in the UK, with Vestas supplying, delivering, commissioning, and servicing the turbines under a comprehensive multi-year agreement. This large UK offshore order highlights how Vestas’ V236 platform and service capabilities are being applied at utility scale across a major European project. We’ll now examine how securing this large Vanguard West...

What Genmab’s recent share performance may be telling investors Genmab (CPSE:GMAB) has seen its share price slip about 10% over the past month and roughly 9% over the past 3 months, which may prompt investors to reassess the biotech’s current valuation. See our latest analysis for Genmab. While the share price is around DKK1,848.5 and the 30 day and 90 day share price returns are both close to a 10% decline, the 1 year total shareholder return of about 15% alongside a weaker 3 year total...

In February 2026, Novo Nordisk reported phase 3 REDEFINE 4 data showing its CagriSema obesity injection delivered less weight loss than Eli Lilly’s Zepbound, while also outlining future high‑dose trials and ongoing REDEFINE and REIMAGINE programs across obesity and type 2 diabetes. At the same time, Novo Nordisk moved to defend its obesity and diabetes franchise with deeper Wegovy price cuts from 2027, an expanded Wegovy 7.2 mg dose in the EU, and new partnerships and pipeline assets,...

Royal Unibrew (CPSE:RBREW) has wrapped up FY 2025 with fourth quarter revenue of DKK 3.8b and basic EPS of DKK 7.0, alongside net income of DKK 345m, setting the tone for how the full year filters through to margins. The company has seen quarterly revenue move from DKK 3.6b and EPS of DKK 4.6 in Q4 2024 to DKK 3.8b and EPS of DKK 7.0 in Q4 2025, with trailing twelve month EPS at DKK 31.4 and net income at DKK 1.6b framing a year where profitability sits at the center of the story for...

Brødrene A & O Johansen (CPSE:AOJ B) closed FY 2025 with Q4 revenue of DKK1.7 billion and basic EPS of DKK3.01, against a backdrop of trailing 12 month EPS of DKK7.4 and net income of DKK200.7 million that sits alongside 22.8% earnings growth over the past year. Over recent periods the company has seen revenue move from DKK5.4 billion on a trailing 12 month basis in Q4 2024 to DKK6.1 billion in Q4 2025. Over the same timeframe, trailing EPS shifted from DKK6.01 to DKK7.4, setting up a story...

TCM Group (CPSE:TCM) has wrapped up FY 2025 with fourth quarter revenue of DKK 333.1 million and basic EPS of DKK 3.27, alongside trailing twelve month EPS of DKK 7.51 on revenue of DKK 1.28b and net income of DKK 77.77 million. Over recent periods, the company has seen quarterly revenue move from DKK 301.4 million and EPS of DKK 2.20 in Q4 2024 to DKK 333.1 million and EPS of DKK 3.27 in Q4 2025. Interim quarters ranged between DKK 277.7 million and DKK 349.1 million of revenue, with EPS...

Why Demant (CPSE:DEMANT) Is Back in Focus for Investors Demant (CPSE:DEMANT) is drawing fresh attention after gaining market share in the US Veterans Affairs hearing aid channel, while at the same time expanding cost saving layoffs at its Danish operations. See our latest analysis for Demant. The recent gain in US Veterans Affairs market share and the expanded cost-saving program comes after a mixed price pattern, with an 8.07% 7-day share price return, a 30-day share price return of 11.11%,...

TORM (CPSE:TRMD A) has just posted its FY 2025 numbers with fourth quarter revenue of US$352.6 million and basic EPS of US$0.88, while trailing twelve month revenue came in at about US$1.3 billion and EPS at US$2.91. The company has seen quarterly revenue move from US$305.4 million in Q4 2024 to US$352.6 million in Q4 2025, with basic EPS shifting from US$0.81 to US$0.88 over the same period, setting up the latest release against a backdrop of tighter net profit margins and mixed earnings...

Why ISS (CPSE:ISS) Is On Investors’ Radar Today ISS (CPSE:ISS) is drawing attention after recent share price moves, with a flat 1 day return but a 7 day decline of 7.46% and mixed performance over the past month and past 3 months. See our latest analysis for ISS. While the recent 7 day share price return of 7.46% decline suggests fading short term momentum, the 1 year total shareholder return of 42.28% and 5 year total shareholder return of 114.76% point to a much stronger longer term picture...

Sydbank (CPSE:ALSYDB) has wrapped up FY 2025 with Q4 revenue of DKK 3.2b and a basic EPS loss of DKK 0.64, capping off a year in which trailing 12 month revenue sits at DKK 8.4b and basic EPS at DKK 35.03. Over recent quarters, revenue has moved from DKK 1.6b in Q4 2024 to between DKK 1.7b and DKK 1.9b through the first three quarters of 2025. Quarterly EPS has ranged from DKK 6.88 to DKK 14.31 before the latest loss, which is prompting a debate among investors about how durable the bank’s...

Recent share performance and business profile ALK-Abelló (CPSE:ALK B) has drawn investor attention after a period where the share price showed mixed short term performance, with a modest move over the past day contrasting with weaker recent weekly and monthly returns. The Denmark based allergy solutions company focuses on immunotherapy treatments, diagnostic products, emergency medicine for severe allergic reactions, and digital tools that support patients in managing respiratory and food...

Why Novozymes stock is back on investors’ radar Novozymes (CPSE:NSIS B), now operating as Novonesis, has caught investor attention after reporting 7% organic sales growth, a 37.1% adjusted EBITDA margin for 2025, and proposing a higher dividend. The company’s board has also called an Annual General Meeting for March 23, 2026. At this meeting, shareholders will vote on dividend plans, board re-elections, and a bylaw change governing where physically attended general meetings can be held in...

NKT (CPSE:NKT) has just wrapped up FY 2025 with fourth quarter revenue of €847 million, basic EPS of €1.77 and net income of €94 million, setting the tone for how the full year is being read by the market. Over the past six quarters, the company has seen quarterly revenue move between €837 million and €945 million while basic EPS ranged from €0.95 to €1.77. On a trailing twelve month basis EPS came in at €4.93 with net income of €264 million, giving investors a clear view of the earnings run...

If you are looking at Novo Nordisk and wondering whether the current share price still lines up with the company’s long term story, you are not alone. The stock last closed at DKK 238.6, with returns of 22.4% decline over 7 days, 39.4% decline over 30 days, 27.8% decline year to date, 61.8% decline over 1 year and 50.0% decline over 3 years, while the 5 year return stands at 19.6%. These swings have arrived alongside ongoing attention on Novo Nordisk’s role in diabetes and weight management...

Why Netcompany Group’s new buyback matters for shareholders Netcompany Group (CPSE:NETC) has put a fresh DKK 750m share buyback programme in place, targeting up to 3,250,000 shares in order to reshape its capital structure and cover share-based incentive commitments. See our latest analysis for Netcompany Group. Netcompany’s new buyback follows a short burst of positive momentum, with a 1-day share price return of 3.25% and a 7-day share price return of 2.71%. This comes against a weaker...

North Media (CPSE:NORTHM) FY 2025 headline numbers North Media (CPSE:NORTHM) has wrapped up FY 2025 with Q4 revenue of DKK356.8 million and basic EPS of DKK1.73, alongside trailing twelve month revenue of DKK1.296 billion and EPS of DKK3.02. Over recent quarters, revenue has moved from DKK343.1 million in Q2 2024 to DKK310.5 million in Q1 2025 and then to DKK356.8 million in Q4 2025. Quarterly EPS has swung from a loss of DKK6.87 in Q1 2025 to a profit of DKK5.29 in Q2 and DKK1.73 in Q4. With...

Jeudan (CPSE:JDAN) has just released its full year 2025 results, reporting sales of DKK 1,751.36 million and net income of DKK 1,000.45 million, alongside an affirmed annual dividend of DKK 3.00 per share. See our latest analysis for Jeudan. Jeudan's latest earnings and dividend affirmation come after a steady build in momentum, with a 30 day share price return of 2.5% and a 4.1% total shareholder return over the past year, even though the 3 year total shareholder return of 14.9% decline...